v3.25.1
Segment - Schedule of Reporting Segment (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Segment Reporting Information [Line Items]    
Revenue $ 7 $ 3
Total research and development expenses 43,447 43,174
Total general and administrative expenses 14,046 13,494
Other operating income, net (119) (1,090)
Total operating expenses 57,374 55,578
Loss from operations (57,367) (55,575)
Interest income, net 3,862 6,819
Other income, net 1,310 1,090
Impairment of other investments 0 (13,001)
Total other income (loss), net 5,172 (5,092)
Net loss (52,195) (60,667)
Reportable segment    
Segment Reporting Information [Line Items]    
Revenue 7 3
Technical operations 21,833 17,271
Clinical development 8,919 8,383
Non-clinical research 5,146 10,528
Facilities and technology 7,549 6,992
Total research and development expenses 43,447 43,174
Business support 9,071 8,916
Corporate expenses and outside services 3,831 3,668
Facilities and technology 1,144 910
Total general and administrative expenses 14,046 13,494
Other operating income, net (119) (1,090)
Total operating expenses 57,374 55,578
Loss from operations (57,367) (55,575)
Interest income, net 3,862 6,819
Other income, net 1,310 1,090
Impairment of other investments 0 13,001
Total other income (loss), net 5,172 (5,092)
Net loss $ (52,195) $ (60,667)